Serum Free Media Market Report 2026

The serum free media market size has grown rapidly in recent years. It will grow from $1.76 billion in 2025 to $1.98 billion in 2026 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to adoption in biopharma production, regulatory push for animal-free components, improved cell growth formulations, increasing biologics manufacturing, technological advances in media development.

The serum free media market size is expected to see rapid growth in the next few years. It will grow to $3.17 billion in 2030 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to expansion in cell & gene therapy, demand for scalable serum-free media, development of optimized formulations, integration with automated bioprocessing, sustainability-focused media solutions. Major trends in the forecast period include animal component-free media, customizable media formulations, optimized growth media for stem cells, integration with bioreactors, single-use bioprocessing media.

The rising prevalence of chronic diseases is expected to drive the growth of the serum-free media market in the coming years. Chronic diseases are long-term conditions that last a year or more and often require ongoing medical care, limiting daily activities. Serum-free media enables researchers to optimize culture conditions for specific cell types, ensuring optimal growth. Additionally, serum-free media allows for the production of particular cell types or performance of specific applications without serum, supporting the development of new therapies and treatments for chronic diseases. For example, in June 2023, the Institute for Health Metrics and Evaluation, a US-based public health research institute, reported that over half a billion people worldwide were living with diabetes, a number expected to more than double to 1.3 billion by 2050. Therefore, the increasing prevalence of chronic diseases is fueling the growth of the serum-free media market.

Key companies in the serum-free media market are focusing on innovative products, such as advanced CAR T-cell manufacturing solutions, to support progress in cell therapy and cancer treatment. CAR T-cell manufacturing involves engineering a patient’s T-cells (a type of immune cell) to express a chimeric antigen receptor (CAR) that targets specific cancer cells. For instance, in May 2023, Lonza, a Switzerland-based pharmaceutical company, launched TheraPEAK T-VIVO Cell Culture Medium. This specialized serum-free medium is designed for the growth and maintenance of various immune cells, particularly for CAR T-cell manufacturing. Its chemically defined, serum-free, and non-animal-origin (NAO) formulation reduces variability and enhances consistency in T-cell culture processes.

In November 2025, Multus Bio, a UK-based provider of advanced cell culture media and bioprocessing ingredients, partnered with Appleton Woods to expand its presence in the UK life sciences market. This collaboration introduces a new range of advanced serum-free media formulations and ingredients, strengthening Multus Bio’s product portfolio and customer reach. Appleton Woods, based in the UK, specializes in providing high-quality laboratory reagents, media, and consumables for research and bioprocessing organizations.

Major companies operating in the serum free media market are Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Irvine Scientific Inc., GE HealthCare Technologies Inc., Corning Inc., Lonza Group AG, Cytiva, Sigma-Aldrich, Bio-Techne Corporation, Serumwerk Bernburg AG, STEMCELL Technologies Inc., MP Biomedicals LLC, InVitria Inc., Takara Bio Inc., HiMedia Laboratories Pvt. Ltd., PAA Laboratories GmbH, PromoCell GmbH, CellGenix GmbH, Biochrom AG, Biological Industries, Pan Biotech GmbH, Biowest SAS, Bovogen Biologicals Pty Ltd.

North America was the largest region in the serum-free media market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the serum free media market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the serum free media market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have raised costs in the serum free media market by increasing prices for imported raw materials, growth factors, amino acids, and culture media components required for cell culture and biopharmaceutical production. Biopharmaceutical companies and research centers in Asia-Pacific and Europe that depend on global suppliers face higher production and development costs. These pressures particularly affect stem cell media, CHO cell media, and protein expression media segments. However, tariffs are driving investments in local formulation facilities and chemically defined media production, supporting greater self-reliance in the serum free media market.

The serum free media market research report is one of a series of new reports that provides serum free media market statistics, including serum free media industry global market size, regional shares, competitors with a serum free media market share, detailed serum free media market segments, market trends and opportunities, and any further data you may need to thrive in the serum free media industry. This serum free media market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Serum-free media is a type of cell culture medium that enables cells to be cultured without the use of animal sera. It is used in cell culture to minimize the risk of contamination and to provide greater control over the physiological responses of the cells.

The main types of serum-free media include Chinese hamster ovary (CHO) cell media, protein expression media, immunology media, insect cell media, hybridoma media, stem cell media, and chemically defined media. Chinese hamster ovary (CHO) cell media is a chemically defined, protein-free, and serum-free medium optimized for CHO cell proliferation and recombinant protein expression in suspension culture. It is applied in various fields such as biopharmaceutical production, tissue engineering, and regenerative medicine, and is used by biopharmaceutical companies, clinical research organizations, academic research centers, and other end-users.

The serum-free media market consists of sales of xeno-free, protein-free, and benchstable media. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.